XSNX Stock Overview
NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
NovAccess Global Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.007 |
| 52 Week High | US$0.22 |
| 52 Week Low | US$0.005 |
| Beta | 1.46 |
| 1 Month Change | -39.74% |
| 3 Month Change | -71.59% |
| 1 Year Change | -96.12% |
| 3 Year Change | -98.60% |
| 5 Year Change | -98.60% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| XSNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.1% | -1.5% | -0.7% |
| 1Y | -96.1% | 0.1% | 22.3% |
Return vs Industry: XSNX underperformed the US Biotechs industry which returned 0.1% over the past year.
Return vs Market: XSNX underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| XSNX volatility | |
|---|---|
| XSNX Average Weekly Movement | 33.0% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XSNX's share price has been volatile over the past 3 months.
Volatility Over Time: XSNX's weekly volatility has decreased from 40% to 33% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 3 | Dwain Morris-Irvin | www.novaccessglobal.com |
NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.
NovAccess Global Inc. Fundamentals Summary
| XSNX fundamental statistics | |
|---|---|
| Market cap | US$244.98k |
| Earnings (TTM) | -US$834.19k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs XSNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XSNX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$834.19k |
| Earnings | -US$834.19k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -36.8% |
How did XSNX perform over the long term?
See historical performance and comparison